☆ 4.2 Article

Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment

IMMUNOTHERAPY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Chemistry, Medicinal

Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective

Choongho Lee et al.

Summary: The novel coronavirus SARS-CoV-2, known as COVID-19, has had a devastating impact on the global economy and healthcare systems, changing the definition of normal life. Developing effective therapeutics and preventive measures is crucial in fighting SARS-CoV-2 infection and restoring normalcy. Understanding COVID-19 pathogenesis is essential in guiding the development of anti-COVID-19 drugs and vaccines.

ARCHIVES OF PHARMACAL RESEARCH (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Ethan Basch et al.

Summary: A composite grading algorithm has been developed to provide single numerical grades for adverse events assessed via the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, and can be useful in analyses and reporting. The algorithm was refined through a five-step process and was found to perform well and comparably to individual item scores on validity, reliability, sensitivity, and between-arm delineation.

CLINICAL TRIALS (2021)

添加到收藏夹

Article Immunology

Complement activation and endothelial perturbation parallel COVID-19 severity and activity

Massimo Cugno et al.

Summary: The study found that complement activation is enhanced during the progression of COVID-19 and dampened during remission, indicating its role in the pathophysiology of the disease. The association between complement activation and the biomarkers of endothelial damage suggests that complement may contribute to tissue injury and could be the target of specific therapy.

JOURNAL OF AUTOIMMUNITY (2021)

添加到收藏夹

Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cell Biology

CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients

M. Hernandez-Cedeno et al.

Summary: This study demonstrates the therapeutic potential of CIGB-258 in COVID-19 patients by reducing levels of biomarkers associated with hyperinflammation, promoting T cell activity, and improving severe conditions.

CELL STRESS & CHAPERONES (2021)

添加到收藏夹

Article Oncology

Use of nimotuzumab combined with cisplatin in treatment of nasopharyngeal carcinoma and its effect on expressions of VEGF and MMP-2

L. Qu et al.

Summary: The combination of nimotuzumab and cisplatin improves conditions and reduces adverse reactions in nasopharyngeal carcinoma patients, with significant decreases in VEGF and MMP-2 expression after treatment. The total remission rate of patients significantly increased after treatment.

CLINICAL & TRANSLATIONAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

添加到收藏夹

Review Medicine, General & Internal

Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection A Systematic Review

Destin Groff et al.

Summary: This systematic review found that more than half of COVID-19 survivors experienced PASC 6 months after recovery, with the most common effects being functional mobility impairments, pulmonary abnormalities, and mental health disorders.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Review Medicine, Research & Experimental

How specific molecular-targeted agents can make obsolete a 'one size fits all' approach in EGFR-mutated NSCLC treatment (Review)

Carmen Popescu et al.

Summary: Despite advancements in lung cancer treatment, high mortality rates persist due to disease aggressiveness and lack of early diagnosis. Personalized treatment approaches and TKIs have shown promise in improving survival for certain patients, but further research is needed to address resistance and increase patient survival. Ongoing clinical trials may lead to changes in therapeutic approaches for EGFR-mutated advanced or metastatic NSCLC patients.

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo- controlled phase 3 trial

Vincent C. Marconi et al.

Summary: Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard care alone, and was associated with reduced mortality in hospitalised adults with COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Review Oncology

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma

Renba Liang et al.

Summary: Combining nimotuzumab with induction chemotherapy, radiotherapy, or concurrent chemoradiotherapy has been shown to benefit NPC patients, with tolerable side effects.

CANCER CONTROL (2021)

添加到收藏夹

Review Immunology

IL-6 in inflammation, autoimmunity and cancer

Toshio Hirano

Summary: IL-6 is involved in various physiological processes including immune responses and inflammation. It plays a crucial role in chronic inflammation and cytokine storms, such as seen in COVID-19. The IL-6 amplifier, involving NF-kappa B and STAT3, is a key mechanism in promoting uncontrolled inflammatory responses.

INTERNATIONAL IMMUNOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

PAI-1 Regulation of TGF-β1-induced Alveolar Type II Cell Senescence, SASP Secretion, and SASP-mediated Activation of Alveolar Macrophages

Tapasi Rana et al.

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2020)

添加到收藏夹

Review Hematology

Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19

Claire S. Whyte et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

添加到收藏夹

Review Oncology

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck

Tania Crombet Ramos et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm

Giuseppe Lippi et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Review Cell Biology

Senescence and Host-Pathogen Interactions

Daniel Humphreys et al.

CELLS (2020)

添加到收藏夹

Review Oncology

COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon

Giuseppe Lippi et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

An aberrant STAT pathway is central to COVID-19

Toshifumi Matsuyama et al.

CELL DEATH AND DIFFERENTIATION (2020)

添加到收藏夹

Article Multidisciplinary Sciences

IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome

Sujin Kang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

添加到收藏夹

Article Immunology

Natural history of COVID-19 and therapeutic options

Philippe Gautret et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

miRNA-9 Inhibits Proliferation and Migration of Lung Squamous Cell Carcinoma Cells by Regulating NRSF/EGFR

Kangning Wang et al.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2020)

添加到收藏夹

Review Oncology

Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies

Christine M. Parseghian et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

EGFR inhibitors from cancer to inflammation: Discovery of 4-fluoro-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide as a novel anti-inflammatory EGFR inhibitor

Ahmed Elkamhawy et al.

BIOORGANIC CHEMISTRY (2019)

添加到收藏夹

Article Oncology

A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial

Gilberto de Castro Junior et al.

EUROPEAN JOURNAL OF CANCER (2018)

添加到收藏夹

Review Oncology

Nimotuzumab: beyond the EGFR signaling cascade inhibition

Zaima Mazorra et al.

SEMINARS IN ONCOLOGY (2018)

添加到收藏夹

Article Oncology

EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo

Chenfei Zhou et al.

CURRENT CANCER DRUG TARGETS (2017)

添加到收藏夹

Article Virology

Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection

Thiagarajan Venkataraman et al.

JOURNAL OF VIROLOGY (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients

Zaima Mazorra et al.

FRONTIERS IN PHARMACOLOGY (2017)

添加到收藏夹

Article

Over-Expression of Egfr is Closely Correlated to Poor Prognosis in Tunisian Patients with Non-Small Cell Lung Adenocarcinoma

Amira Arfaoui et al.

JOURNAL OF IMMUNOASSAY & IMMUNOCHEMISTRY (2013)

添加到收藏夹

Article Oncology

Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues

Hong Liang et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer

C. Alberti et al.

ONCOGENE (2012)

添加到收藏夹

Article Oncology

Inhibition of telomerase activity by HDV ribozyme in cancers

Yingying Lu et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2011)

添加到收藏夹

Article Oncology

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects

Rolando Perez et al.

Cancers (2011)

添加到收藏夹

Article Critical Care Medicine

Gefitinib prevents bleomycin-induced lung fibrosis in mice

Yoshiki Ishii et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)

添加到收藏夹

Review Oncology

Epidermal growth factor receptor targeting in cancer

John Mendelsohn et al.

SEMINARS IN ONCOLOGY (2006)

添加到收藏夹

Article Oncology

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients

T Crombet et al.

JOURNAL OF CLINICAL ONCOLOGY (2004)

添加到收藏夹

Article Oncology

Antiproliferative, antiangiogenic and proapoptotic activity of h-R3:: A humanized anti-EGFR antibody

T Crombet-Ramos et al.

INTERNATIONAL JOURNAL OF CANCER (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.